{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:36:16Z","timestamp":1787567776268,"version":"build-2736575974"},"reference-count":22,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    TV\u201044749 is a long\u2010acting subcutaneous (SC) injectable olanzapine based on a novel copolymer drug delivery technology ensuring controlled olanzapine release over the dosing interval. TV\u201044749's formulation and SC route of administration aim to eliminate the causes of post\u2010injection delirium\/sedation syndrome (PDSS) that may occur with the intramuscular LAI olanzapine formulation. The main objective of this analysis was to utilize a population pharmacokinetic (PPK) modeling and simulation approach to select TV\u201044749 doses for a Phase 3 clinical trial that are comparable to the oral olanzapine approved doses and achieve dopamine D2 receptor occupancy (D2RO) within the therapeutic range. The PPK model was developed using data from a Phase 1 study in healthy participants and patients with schizophrenia or schizoaffective disorder. The Phase 1 study consisted of an oral olanzapine period followed by a washout and then single or multiple doses of TV\u201044749. The PK model was characterized by a double Weibull input function representing a two\u2010phase drug release: an initial rapid release of a fraction of the dose, followed by a delayed and sustained release of a second fraction with two\u2010compartment disposition model. The predicted steady\u2010state pharmacokinetic parameters (C\n                    <jats:sub>max<\/jats:sub>\n                    , C\n                    <jats:sub>avg<\/jats:sub>\n                    , and C\n                    <jats:sub>trough<\/jats:sub>\n                    ) of once\u2010monthly TV\u201044749 doses of 318, 425, and 531 mg were comparable to daily oral doses of 10, 15, and 20 mg, respectively. The exposure values resulted in simulated D2RO levels within the recommended range (60%\u201380%) and were therefore selected for the Phase 3 trial of TV\u201044749 (SOLARIS; NCT05693935).\n                  <\/jats:p>","DOI":"10.1002\/jcph.70144","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T05:51:51Z","timestamp":1767765111000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Model\u2010Based Dose Selection of Extended\u2010Release Injectable Olanzapine (TV\u201044749) for Subcutaneous Use in Phase 3 Clinical Trial in Adults with Schizophrenia"],"prefix":"10.1002","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8700-3957","authenticated-orcid":false,"given":"Itay","family":"Perlstein","sequence":"first","affiliation":[{"name":"Magic Wand Research LLC  Philadelphia PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Cherniakov","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Ltd.  Netanya Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Elgart","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Ltd.  Netanya Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Gomeni","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Ltd.  Netanya Israel"},{"name":"PharmacoMetrica  La Fouillade France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dikla","family":"Gutman","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Ltd.  Netanya Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avia","family":"Merenlender Wagner","sequence":"additional","affiliation":[{"name":"Teva Pharmaceutical Industries, Ltd.  Netanya Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2719-4573","authenticated-orcid":false,"given":"Rajendra","family":"Singh","sequence":"additional","affiliation":[{"name":"Teva Branded Pharmaceutical Products R&amp;D LLC  West Chester PA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"issue":"9","key":"e_1_2_11_2_1","first-page":"638","article-title":"Schizophrenia: overview and treatment options","volume":"39","author":"Patel KR","year":"2014","journal-title":"P T"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1078"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01671-6"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.4437"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.4103\/0019-5545.43632"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbx009"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.3.241"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.08.024"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_2_11_11_1","unstructured":"Eli Lilly and Company.ZYPREXA (olanzapine) prescribing information [label]. In:Eli Lilly and Company;2025."},{"key":"e_1_2_11_12_1","unstructured":"Neon Healthcare Ltd.ZYPADHERA 300 mg powder and solvent for prolonged\u2010release suspension for injection: Summary of product characteristics. In:UK: Neon Healthcare Ltd;2024."},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2023.102503"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301409"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.724"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-020070"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.26"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sby058"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2023.2219055"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2013.09.023"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3182214aad"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.22r14626"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0251-1"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70144","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70144","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T09:42:55Z","timestamp":1787564575000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/jcph.70144"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70144","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2025-03-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70144"}}